A pilot multicentre randomised clinical trial to determine the effect of a pharmacist‐partnered opioid tapering intervention before total hip or knee arthroplasty
Authors' conclusion
The findings of this pilot study support the feasibility of a telehealth-delivered, pharmacist-partnered opioid tapering service for patients scheduled for primary hip or knee arthroplasty.
Study context
- Population
- Adults (≥ 18 years) taking opioid analgesics pre-operatively, scheduled for primary hip or knee arthroplasty for osteoarthritis, 7 hospitals in New South Wales, Australia30 per group completed
- Participants
- 70 adults
- Comparison
- Intervention vs Usual care
- Interventionn = 35
- Usual caren = 35reference
- Primary endpoint
- Feasibility (adherence to treatment) and potential effectiveness in decreasing baseline daily opioid dose by > 50% before surgery
- Follow-up
- Before surgery
Methodological detailspilot, multicentre
- Pilot
- Multicentre
Primary result
As reported in the abstract
Baseline daily opioid dose decreased by ≥ 50% before surgery
Intervention
27 of 30
27 of 35
Usual care
5 of 30
5 of 35
P < 0.001
Further findings
- Feasibility: pharmacist appointments (intervention)
- 2 · median · IQR [range] 1-4 [1-6] · appointments
Feasibility: pharmacist appointments (intervention)
- All intervention patients completed at least one pharmacist appointment
Original publication
A pilot multicentre randomised clinical trial to determine the effect of a pharmacist‐partnered opioid tapering intervention before total hip or knee arthroplasty. Anaesthesia. Published 31 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →